Frontotemporal dementia treatment: Current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies

Adam L. Boxer, Bradley F. Boeve

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administration-approved medications for FTD although symptomatic treatments such as selective serotonin reuptake inhibitors and atypical antipsychotic agents are frequently used to manage behavioral abnormalities associated with this disorder. Evidence for the use of currently available symptomatic treatments in each FTD clinical subtype is reviewed. In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed.

Original languageEnglish (US)
Pages (from-to)S79-S87
JournalAlzheimer disease and associated disorders
Volume21
Issue number4
DOIs
StatePublished - Oct 2007

Keywords

  • Antipsychotic
  • Cholinesterase inhibitor
  • Frontotemporal dementia
  • Frontotemporal lobar degeneration
  • Primary progressive aphasia
  • Progressive nonfluent aphasia
  • Selective serotonin reuptake inhibitor (SSRI)
  • Semantic dementia
  • Treatment

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Frontotemporal dementia treatment: Current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies'. Together they form a unique fingerprint.

  • Cite this